Please assess the completion status of the following clinical trial:

Trial Title: TAF for HIV-HBV With Renal Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV/HBV-coinfection~* Suppressed HIV-viremia (\<200 cp/ml)~* On TDF-containing ART since at least 6 months~* eGFR \> 30 ml/min and \<90 ml/min~* Written informed consent~Exclusion Criteria:~* Study drug considered by the treating physician not a valid option for the patient~* Pregnancy~* Decompensated liver cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Switch (Type: EXPERIMENTAL): Patients are switched from a TDF-containing antiretroviral therapy regimen to a TAF-containing regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).